A number of other analysts also recently weighed in on CUTR. BidaskClub raised shares of Cutera from a buy rating to a strong-buy rating in a research report on Saturday, July 13th. Zacks Investment Research raised shares of Cutera from a sell rating to a hold rating in a research report on Tuesday, July 9th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $34.67.
Cutera stock opened at $32.85 on Friday. The firm has a 50 day moving average price of $24.23. Cutera has a 1 year low of $12.32 and a 1 year high of $35.85. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.66 and a quick ratio of 1.09. The firm has a market capitalization of $461.12 million, a P/E ratio of -14.73 and a beta of 0.88.
In other news, Director J Daniel Plants bought 14,011 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was acquired at an average price of $16.93 per share, with a total value of $237,206.23. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 42,377 shares of company stock valued at $711,717 in the last three months. Insiders own 2.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in shares of Cutera by 1.8% during the 2nd quarter. BlackRock Inc. now owns 2,054,106 shares of the medical device company’s stock worth $42,684,000 after buying an additional 36,851 shares in the last quarter. Gamco Investors INC. ET AL boosted its holdings in shares of Cutera by 2.0% during the 2nd quarter. Gamco Investors INC. ET AL now owns 1,122,546 shares of the medical device company’s stock worth $23,327,000 after buying an additional 21,745 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in shares of Cutera by 96.4% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 834,500 shares of the medical device company’s stock worth $14,737,000 after buying an additional 409,700 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Cutera by 7.4% during the 2nd quarter. Renaissance Technologies LLC now owns 648,600 shares of the medical device company’s stock worth $13,478,000 after buying an additional 44,600 shares in the last quarter. Finally, Gabelli Funds LLC boosted its holdings in shares of Cutera by 5.6% during the 1st quarter. Gabelli Funds LLC now owns 644,807 shares of the medical device company’s stock worth $11,387,000 after buying an additional 34,400 shares in the last quarter. 92.39% of the stock is owned by institutional investors and hedge funds.
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Further Reading: Marijuana Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.